Yoon Young-In, Song Gi-Won, Lee SungGyu, Moon DeokBog, Hwang Shin, Kang Woo-Hyoung, Cho Hwui-Dong, Ha Su-Min, Kim Min-Jae, Kim Sang-Hoon, Na Byeong-Gon, Yang Geunhyeok, Min Kim Sung, Hyun Shim Ju, Park Jeong-Ik
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Am J Transplant. 2022 Jan;22(1):165-176. doi: 10.1111/ajt.16790. Epub 2021 Sep 2.
Following curative liver resection (LR), resectable tumor recurrence in patients with preserved liver function leads to deciding between a repeat LR and a salvage liver transplantation (LT), if a donor's liver is available. This retrospective study compared survival outcomes and recurrence pattern following salvage living donor LT (LDLT) and repeat LR in patients with recurrent hepatocellular carcinoma (HCC). We reviewed the medical records of patients who underwent repeat LR (n = 163) or LDLT (n = 84) for recurrent HCC following curative resections, between January 2005 and December 2017 at a single institution. A 1:1 propensity score matching led to 42 patients per group. Disease-specific and recurrence-free survival were significantly better in the salvage LDLT group than in the repeat LR group (p = .042; HR = 2.40; 95% CI, 0.69-6.00 and p < .001; HR = 4.23; 95% CI, 2.05-8.71, respectively). Despite significant differences in recurrence patterns between the two groups (p = .019), the patient death rates, after recurrence, were similar for both groups (p = .760). This study indicates that salvage LDLT is superior to repeat LR for treating patients with transplantable, intrahepatic HCC recurrence, even in patients with Child-Pugh class A liver cirrhosis.
在进行根治性肝切除(LR)后,肝功能保留的患者出现可切除的肿瘤复发时,如果有供体肝脏,就需要在再次LR和挽救性肝移植(LT)之间做出抉择。这项回顾性研究比较了复发性肝细胞癌(HCC)患者接受挽救性活体供体LT(LDLT)和再次LR后的生存结果及复发模式。我们回顾了2005年1月至2017年12月在单一机构接受根治性切除术后因复发性HCC接受再次LR(n = 163)或LDLT(n = 84)的患者的病历。通过1:1倾向评分匹配,每组各有42例患者。挽救性LDLT组的疾病特异性生存率和无复发生存率显著优于再次LR组(p = .042;HR = 2.40;95% CI,0.69 - 6.00;以及p < .001;HR = 4.23;95% CI,2.05 - 8.71)。尽管两组的复发模式存在显著差异(p = .019),但两组复发后的患者死亡率相似(p = .760)。这项研究表明,对于可移植的肝内HCC复发患者,即使是Child-Pugh A级肝硬化患者,挽救性LDLT也优于再次LR。